SPDR S&P Biotech (NYSEARCA:XBI) Stake Maintained by Sonata Capital Group Inc.

Sonata Capital Group Inc. maintained its stake in shares of SPDR S&P Biotech (NYSEARCA:XBI) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,450 shares of the exchange traded fund’s stock at the end of the second quarter. Sonata Capital Group Inc.’s holdings in SPDR S&P Biotech were worth $266,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the stock. Papp L Roy & Associates boosted its position in SPDR S&P Biotech by 3.1% in the second quarter. Papp L Roy & Associates now owns 187,538 shares of the exchange traded fund’s stock valued at $14,474,000 after buying an additional 5,648 shares during the period. Weatherly Asset Management L. P. boosted its position in SPDR S&P Biotech by 4.5% in the second quarter. Weatherly Asset Management L. P. now owns 125,537 shares of the exchange traded fund’s stock valued at $9,689,000 after buying an additional 5,374 shares during the period. Janney Montgomery Scott LLC boosted its position in SPDR S&P Biotech by 10.9% in the second quarter. Janney Montgomery Scott LLC now owns 98,057 shares of the exchange traded fund’s stock valued at $7,568,000 after buying an additional 9,655 shares during the period. Rand Wealth LLC boosted its position in SPDR S&P Biotech by 1.8% in the second quarter. Rand Wealth LLC now owns 49,147 shares of the exchange traded fund’s stock valued at $3,793,000 after buying an additional 863 shares during the period. Finally, Russell Investments Group Ltd. boosted its position in SPDR S&P Biotech by 61.7% in the second quarter. Russell Investments Group Ltd. now owns 49,141 shares of the exchange traded fund’s stock valued at $3,792,000 after buying an additional 18,746 shares during the period.

Shares of SPDR S&P Biotech (NYSEARCA XBI) traded down 0.11% during mid-day trading on Friday, reaching $74.95. 4,771,566 shares of the company were exchanged. The firm has a 50-day moving average price of $78.04 and a 200 day moving average price of $72.03. SPDR S&P Biotech has a 12 month low of $53.15 and a 12 month high of $82.38.

ILLEGAL ACTIVITY WARNING: “SPDR S&P Biotech (NYSEARCA:XBI) Stake Maintained by Sonata Capital Group Inc.” was posted by Rincon Hill News and is the property of of Rincon Hill News. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://rinconhillneighbors.org/2017/08/19/sonata-capital-group-inc-holds-position-in-spdr-sp-biotech-nysearcaxbi-updated.html.

About SPDR S&P Biotech

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Institutional Ownership by Quarter for SPDR S&P Biotech (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech and related companies with our FREE daily email newsletter.

 

Latest News



Leave a Reply

 
© 2006-2017 Rincon Hill News.